Clinical Trial Search

Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants

Primary: Change From Baseline to Week 24 in Muscle Strength — 0.4 score on a scale

Primary: Number of Participants With Plasma Uric Acid (UA) Response — 39; 34 participants

Primary: Number of Participants in Population 1 With a Clinical Response at Week 8 — 13; 12; 8; 13 participants — p=0.337

Primary: Number of Evaluable Participants With Complete Response (CR) and Partial Response (PR) at One Year — 0; 1 participants

Primary: Change From Baseline of Chamomile Extract on Measures of Sleep at Day 28. — 83.3; 77.5 percentage of time asleep — p=0.21

Primary: Tumor Response, Defined by Disease: Chronic Lymphocytic Leukemia(CLL): Clinical Complete or Complete or Nodular Partial or Partial Remission, Waldenstrom: Complete or…

Primary: Plaque Index of Test Mouth Rinse Versus Sterile Water After Day 4 of Treatment Administration — 3.03; 3.23 Score on a scale — p=0.0915

Primary: Number of Patients With Complete Response — 14; 3 participants

Primary: Binge Frequency — 10.4; 11.3 Binge Episodes/Week — p=<.05

Primary: Incidences of Device-related or Procedure-related Complications — 1 participants

Primary: Baseline Retic Count — 122; 140 x1000 cells/microliter

Primary: Percentage of Participants With Sustained Pain Control for 5 Day Fixed Dose Phase — 89.7; 92.9 percentage of participants

Primary: 6 Month Progression-Free Survival (PFS) — 41; 44 percentage of participants

Primary: The Maximally Tolerated Dose (MTD) of Bortezomib (Velcade) That Can be Administered With Tacrolimus and Methotrexate After Mismatched Allogeneic Non-myeloablative…